Division of Neurosurgery, St. Michael's Hospital, 30 Bond Street, Toronto, ON, M5B 1W8, Canada,
Neurocrit Care. 2013 Oct;19(2):140-9. doi: 10.1007/s12028-013-9860-z.
Delayed ischemic neurological deficit (DIND) following aneurysmal subarachnoid hemorrhage (SAH) remains a significant cause of mortality and disability. The administration of colloids and the induction of a positive fluid balance during the vasospasm risk period remain controversial. Here, we compared DIND and outcomes among propensity score-matched cohorts who did and did not receive colloids and also tested the effect of a positive fluid balance on these endpoints.
Exploratory analysis was performed on 413 patients enrolled in CONSCIOUS-1, a prospective randomized trial of clazosentan for the prevention of angiographic vasospasm. Propensity score matching was performed on the basis of age, gender, pre-existing heart conditions, hypertension, nicotine use, World Federation of Neurosurgical Societies scores, aneurysm location, clazosentan treatment, subarachnoid clot burden, and severity of angiographic vasospasm. Inferential statistics were used for group-wise comparisons.
One hundred twenty-three subjects were matched (41 received colloids, whereas 82 did not). The covariate balance and propensity score distributions were acceptable. There was no difference between the groups with respect to DIND (17 vs. 22%; p = 0.64) or the presence (48 vs. 51%; p = 0.71) or volume of delayed infarcts (volume >7.5 cm3; 62 vs. 48%; p = 0.41). Similarly, no differences were found on multivariate analysis between patients who did and did not have a positive fluid balance, although patients with severe angiographic vasospasm had more delayed infarcts with a negative fluid balance (p = 0.01). Among all subjects, the administration of colloids and a positive fluid balance were associated with worse outcomes on the NIHSS (p = 0.04) and modified Rankin (p = 0.02) scales, respectively.
Colloid administration and induction of a positive fluid balance during the vasospasm risk period may be associated with poor outcomes in specific patient groups. Patient selection is of utmost importance when managing the fluid status of patients with aneurysmal SAH.
动脉瘤性蛛网膜下腔出血(SAH)后迟发性缺血性神经功能缺损(DIND)仍然是死亡和残疾的重要原因。在血管痉挛风险期输注胶体和诱导正液体平衡仍然存在争议。在这里,我们比较了接受和未接受胶体的倾向评分匹配队列中的 DIND 和结局,并测试了正液体平衡对这些终点的影响。
对参加 CONSCIOUS-1 的 413 名患者进行了探索性分析,该研究是一项前瞻性随机氯苯唑酸预防血管造影性血管痉挛的试验。基于年龄、性别、既往心脏状况、高血压、尼古丁使用、世界神经外科学会评分、动脉瘤位置、氯苯唑酸治疗、蛛网膜下腔积血、血管造影性血管痉挛严重程度进行倾向评分匹配。使用推断统计学进行组间比较。
123 例患者匹配(41 例接受胶体,82 例未接受胶体)。协变量平衡和倾向评分分布是可以接受的。两组在 DIND 方面无差异(17% vs. 22%;p = 0.64)或迟发性梗死的存在(48% vs. 51%;p = 0.71)或体积(体积>7.5cm3;62% vs. 48%;p = 0.41)。同样,在多变量分析中,没有发现有正液体平衡和没有正液体平衡的患者之间存在差异,尽管血管造影性血管痉挛严重的患者负液体平衡时迟发性梗死更多(p = 0.01)。在所有患者中,胶体的给予和正液体平衡与 NIHSS(p = 0.04)和改良 Rankin(p = 0.02)评分的不良结局相关。
在血管痉挛风险期输注胶体和诱导正液体平衡可能与特定患者群体的不良结局相关。在管理动脉瘤性蛛网膜下腔出血患者的液体状态时,患者选择至关重要。